Full-course oral levofloxacin for treatment of hospitalized patients with community-acquired pneumonia

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 23, Issue 2, 2004, Pages 82-88

  Erard, V ^a   Lamy, O ^a   Bochud, P Y ^a   Bille, J ^a   Cometta, A ^a,b   Calandra, T ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Centre Hospitalier Yverdon Chamblon   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFPODOXIME; CEFTRIAXONE; CEFUROXIME; CLARITHROMYCIN; GATIFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; OFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; CLINICAL PROTOCOL; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EVALUATION; FEMALE; FOLLOW UP; HEALTH CARE COST; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NAUSEA; OPEN STUDY; OUTCOMES RESEARCH; PATIENT CARE; PILOT STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEIZURE;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; COMMUNITY-ACQUIRED INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HOSPITALS, TEACHING; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; OFLOXACIN; PILOT PROJECTS; PNEUMONIA, BACTERIAL; PROBABILITY; PROSPECTIVE STUDIES; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 1642271798     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-003-1060-x     Document Type: Article

References (37)

1. Anonymous (2001) BTS guidelines for the management of community-acquired pneumonia in adults. Thorax 56 (Suppl 4):1-64
2. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ (2000) Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 31:347-382
3. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH (2000) Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 31:383-421
4. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL (2001) Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 163:1730-1754
5. Hirata-Dulas CA, Stein DJ, Guay DR, Gruninger RP, Peterson PK (1991) A randomized study of ciprofloxacin versus ceftriaxone in the treatment of nursing home-acquired lower respiratory tract infections. J Am Geriatr Soc 39:979-985
6. Ramirez JA, Srinath L, Ahkee S, Huang A, Raff MJ (1995) Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med 155:1273-1276
7. Hendrickson JR, North DS (1995) Pharmacoeconomic benefit of antibiotic step-down therapy: converting patients from intravenous ceftriaxone to oral cefpodoxime proxetil. Ann Pharmacother 29:561-565
8. Chan R, Hemeryck L, O'Regan M, Clancy L, Feely J (1995) Oral versus intravenous antibiotics for community-acquired lower respiratory tract infection in a general hospital: open, randomised controlled trial. Br Med J 310:1360-1362
9. Oh HM, Ng AW, Lee SK (1996) Cefuroxime compared to amoxicillin- clavulanic acid in the treatment of community-acquired pneumonia. Singapore Med J 37:255-257
10. Siegel RE, Halpern NA, Almenoff PL, Lee A, Cashin R, Greene JG (1996) A prospective randomized study of inpatient iv. antibiotics for community-acquired pneumonia. The optimal duration of therapy. Chest 110:965-971
11. Ramirez JA, Vargas S, Ritter GW, Brier ME, Wright A, Smith S, Newman D, Burke J, Mushtaq M, Huang A (1999) Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med 159:2449-2454
12. Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG (2000) A controlled trial of a critical pathway for treatment of community-acquired pneumonia. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA 283:749-755
13. Vogel F (2002) Intravenous/oral sequential therapy in patients hospitalised with community-acquired pneumonia: which patients, when and what agents? Drugs 62:309-317
14. File TM Jr, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, Kojak C, Rubin A (1997) A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 41:1965-1972
15. Norrby SR, Petermann W, Willcox PA, Vetter N, Salewski E (1998) A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand J Infect Dis 30:397-404
16. Work Group for Practice Guidelines for Community-Acquired Pneumonia (1999) Diagnostic and treatment of community-acquired pneumonia in the adult. Recommendations for clinical practice. Rev Med Suisse Romande 119:403-427
17. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41
18. Wong LK, Barry AL, Horgan SM (1982) Comparison of six different criteria for judging the acceptability of sputum specimens. J Clin Microbiol 16:627-631
19. Reisner BA, Woods GL, Thomson RB, Larone DH, Garcia LS, Shimizu RY (2002) Specimen processing. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (eds) Manual of clinical microbiology. ASM Press, Washington DC, pp 64
20. Jorgensen JH, Turnidge JD, Washington JA (1999) Antibacterial susceptibility tests: dilution and disk diffusion. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (eds) Manual of clinical microbiology, 7th edn. ASM Press, Washington DC, pp 1526-1543
21. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN (1997) A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336:243-250
22. O'Doherty B, Dutchman DA, Pettit R, Maroli A (1997) Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother 40 (Suppl A):73-81
23. Ramirez J, Unowsky J, Talbot GH, Zhang H, Townsend L (1999) Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia. Clin Ther 21:103-117
24. Lode H, Garau J, Grassi C, Hosie J, Huchon G, Legakis N, Segev S, Wijnands G (1995) Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin. Eur Respir J 8:1999-2007
25. Ortqvist A, Valtonen M, Cars O, Wahl M, Saikku P, Jean C (1996) Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. The Scandinavian Sparfloxacin Study Group. Chest 110:1499-1506
26. Tremolieres F, de Kock F, Pluck N, Daniel R (1998) Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia. Eur J Clin Microbiol Infect Dis 17:447-453
27. Carbon C, Ariza H, Rabie WJ, Salvarezza CR, Elkharrat D, Rangaraj M, Decosta P (1999) Comparative study of levofloxacin and amoxycillin/clavulanic acid in adults with mild-to-moderate community acquired pneumonia. Clin Microbiol Infect 5:724-732
28. Moola S, Hagberg L, Churchyard GA, Dylewski JS, Sedani S, Staley H (1999) A multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia. Chest 116:974-983
29. Petitpretz P, Arvis P, Marel M, Moita J, Urueta J (2001) Oral moxifloxacin vs. high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest 119:185-195
30. Chen DK, McGeer A, de Azavedo JC, Low DE (1999) Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med 341:233-239
31. Davidson R, Cavalcanti R, Brunton JL, Bast DJ, de Azavedo JC, Kibsey P, Fleming C, Low DE (2002) Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 346:747-750
32. Fredlund H, Bodin L, Back E, Holmberg H, Krook A, Rydman H (1987) Antibiotic therapy in pneumonia: a comparative study of parenteral and oral administration of penicillin. Scand J Infect Dis 19:459-466
33. Zuck P, Rio Y, Ichou F (1990) Efficacy and tolerance of cefpodoxime proxetil compared with ceftriaxone in vulnerable patients with bronchopneumonia. J Antimicrob Chemother 26 (Suppl E):71-77
34. Sanders WE Jr, Morris JF, Alessi P, Makris AT, McCloskey RV, Trenholme GM, Iannini P, Bittner MJ (1991) Oral ofloxacin for the treatment of acute bacterial pneumonia: use of a nontraditional protocol to compare experimental therapy with "usual care" in a multicenter clinical trial. Am J Med 91:261-266
35. Bohte R, van't Wout JW, Lobatto S, Blusse van Oud AA, Boekhout M, Nauta EH, Hermans J, van den Broek PJ (1995) Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 14:182-187
36. Castro-Guardiola A, Viejo-Rodriguez AL, Soler-Simon S, Armengou-Arxe A, Bisbe-Company, Penarroja-Matutano G, Bisbe-Company, Garcia-Bragado F (2001) Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia: a randomized controlled trial. Am J Med 111:367-374
37. Aubier M, Verster R, Regamey C, Geslin P, Vercken JB (1998) Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults. Sparfloxacin European Study Group. Clin Infect Dis 26:1312-1320